- Home
- CELC vs CHW Comparison
CELC vs CHW Comparison
Compare CELC & CHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- CHW
- Stock Information
- Founded
- CELC 2011
- CHW 2007
- Country
- CELC United States
- CHW United States
- Employees
- CELC N/A
- CHW N/A
- Industry
- CELC Medical Specialities
- CHW Investment Managers
- Sector
- CELC Health Care
- CHW Finance
- Exchange
- CELC Nasdaq
- CHW Nasdaq
- Market Cap
- CELC 327.3M
- CHW 383.8M
- IPO Year
- CELC 2017
- CHW N/A
- Fundamental
- Price
- CELC $10.24
- CHW $6.03
- Analyst Decision
- CELC Strong Buy
- CHW
- Analyst Count
- CELC 6
- CHW 0
- Target Price
- CELC $30.17
- CHW N/A
- AVG Volume (30 Days)
- CELC 392.7K
- CHW 195.2K
- Earning Date
- CELC 05-14-2025
- CHW 01-01-0001
- Dividend Yield
- CELC N/A
- CHW 9.27%
- EPS Growth
- CELC N/A
- CHW N/A
- EPS
- CELC N/A
- CHW N/A
- Revenue
- CELC N/A
- CHW N/A
- Revenue This Year
- CELC N/A
- CHW N/A
- Revenue Next Year
- CELC N/A
- CHW N/A
- P/E Ratio
- CELC N/A
- CHW N/A
- Revenue Growth
- CELC N/A
- CHW N/A
- 52 Week Low
- CELC $7.58
- CHW $5.07
- 52 Week High
- CELC $19.77
- CHW $6.54
- Technical
- Relative Strength Index (RSI)
- CELC 54.38
- CHW 42.46
- Support Level
- CELC $7.58
- CHW $5.93
- Resistance Level
- CELC $10.48
- CHW $6.10
- Average True Range (ATR)
- CELC 1.04
- CHW 0.23
- MACD
- CELC 0.17
- CHW 0.01
- Stochastic Oscillator
- CELC 80.01
- CHW 61.82
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About CHW Calamos Global Dynamic Income Fund
Calamos Global Dynamic Income Fund operates as a closed-end management investment company. The company's investment objective is to generate a high level of current income with the objective of capital appreciation. It dynamically allocates its investment among equities, convertible bonds, fixed-income securities and alternative investments.